Sublocade (buprenorphine) is a brand-name extended-release injection that’s prescribed for opioid use disorder. Sublocade has interactions with alcohol, some other drugs, and certain supplements.
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
(RTTNews) - Indivior Plc.(INDV) announced that the U.S. Food and Drug Administration has granted Priority Review designation for the Prior Approval Supplement of SUBLOCADE (buprenorphine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback